Phage display services

Yes. Our phage display platform is designed to handle challenging targets, including complex, unstable, toxic, or low-immunogenic antigens. With more than 500 successful phage display projects, we routinely deliver high-quality binders even when targets are difficult to express or highly conformational.

We can work with a wide range of antigen formats, including peptides, proteins, small molecules, and whole cells. For membrane proteins and clinical targets where native conformation matters, we recommend cell-based panning to select binders that recognize the target in a physiologically relevant form.

We’ve developed an optimized process for phage display to perform negative selection and/or competitive elution to ensure you obtain the antibodies with the ideal specificity and/or activity like a neutralizing activity.

Primary hit identification is based on ELISA screening to confirm binding and select high-affinity candidates. If your application requires a specific validation format, we can further screen individual clones by ELISA, Western blot, or flow cytometry on whole cells. We also offer affinity (KD) measurement as a downstream characterization step.

Our libraries and screening services are available in scFv, Fab, and VHH formats to match your application. After hit discovery, we can clone your sequences into expression vectors and produce recombinant antibodies in the format best suited to your next steps.

Yes. Your deliverables include a complete report with the DNA and amino-acid sequences of selected clones. You also receive full rights to the sequences so you can freely develop, engineer, or manufacture your antibodies.

Your dedicated PhD-level account manager will be happy to discuss about specific panning strategy you would like to use and advise on the best possible option to increase your chances of success.

Upon customer request, we can perform counter-selection and use a dedicated phage display strategy to enrich the number of candidates binding to the protein of interest and not to proteins which should not be recognized.

We combine multiple rounds of biopanning with ELISA-based screening to enrich and confirm high-affinity, specific binders. When relevance to native biology is critical, for example with membrane proteins, we use whole-cell panning to keep the target in its natural conformation and select antibodies that perform in real conditions.

Thanks to our pre-built libraries and optimized workflow, you can receive validated antibodies in as little as 4 weeks. 

Yes. Our phage display libraries are proprietary and exclusive to ProteoGenix, giving you access to resources no other provider can offer. They combine extensive diversity across species and formats with exceptional quality, including an in-frame frequency above 93 percent, which translates into a higher probability of strong, developable hits.

SDS-PAGE and concentration determination by UV280/Bradford are performed in standard, but we can perform many other QCs on purified antibodies, such as : ELISA, SPR/BLI, SEC-HPLC, nanoDSF, MS, endotoxin assay…

Yes. Beyond screening, we can support every next step, including affinity maturation, humanization, and reformatting into advanced formats such as bispecific antibodies or ADCs. We also provide cloning, recombinant production, and in-depth characterization to accelerate your program.

Yes. Our phage display services are built to support research, diagnostic, and therapeutic programs. We tailor the library choice and validation strategy to your application so you get binders that perform in your conditions.

Our phage display services are fully customizable. You can rely on us for the full discovery journey, from library selection to validated binders, or request screening-only support for a specific step. Every project gives you access to our complete portfolio of proprietary libraries. If you prefer to run screening internally, you can also purchase a library with full usage freedom and no hidden fees.

Yes. After selection, we can subclone your antibody cDNAs into expression vectors and produce recombinant antibodies in the format and scale required for your workflow. We can guide you from high-throughput expression and screening to large-scale transient expression and stable cell line development.

We can extend screening to confirm performance in your specific assay, produce recombinant antibodies, engineer next-generation formats, and run advanced characterization such as affinity or stability testing. This lets you move seamlessly from hit discovery to development with one single partner.

We can also provide additional services such as long-term storage. For a one-time fee, ProteoGenix can manage storage for 1 year or indefinitly.